Amgen Inc. $AMGN Stake Increased by Sectoral Asset Management Inc.

Sectoral Asset Management Inc. increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 26.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 13,070 shares of the medical research company’s stock after purchasing an additional 2,730 shares during the period. Amgen accounts for 3.4% of Sectoral Asset Management Inc.’s investment portfolio, making the stock its 6th largest position. Sectoral Asset Management Inc.’s holdings in Amgen were worth $4,278,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Dogwood Wealth Management LLC lifted its holdings in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Anfield Capital Management LLC lifted its holdings in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen during the 4th quarter worth about $26,000. Manning & Napier Advisors LLC lifted its holdings in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC purchased a new stake in Amgen during the 4th quarter worth about $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of Amgen stock opened at $339.30 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $183.11 billion, a PE ratio of 23.61, a price-to-earnings-growth ratio of 3.41 and a beta of 0.44. The business’s 50-day moving average price is $345.10 and its 200-day moving average price is $344.72. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts forecast that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. Amgen’s dividend payout ratio is 70.15%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AMGN. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. The Goldman Sachs Group raised their price target on Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a report on Friday, May 1st. Rothschild & Co Redburn raised their price target on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. Guggenheim lowered their price target on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Finally, Citigroup raised their price target on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $355.19.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen expanded its lung cancer pipeline by launching a phase 1b study testing a tarlatamab combination in small cell lung cancer, which could improve the company’s oncology growth prospects if the data are encouraging. Amgen Expands Lung Cancer Pipeline With New Tarlatamab Combo Study
• Positive Sentiment: Several reports highlighted Amgen as a long-term value/dividend and pipeline story, citing upside potential and analyst support such as an Overweight rating from Piper Sandler, reinforcing confidence in the company’s revenue growth outlook. Why Wall Street Thinks This Dividend Stock Could Jump 30%
• Positive Sentiment: Amgen shareholders reaffirmed the board, executive pay and auditors, which signals governance stability and removes a potential overhang. Amgen Shareholders Reaffirm Board, Pay and Auditors
• Neutral Sentiment: Amgen appointed Thomas Dittrich as chief financial officer, a management update that should be watched for any strategic or capital-allocation changes, but is not clearly a near-term stock catalyst. CFOs On the Move: Week ending May 22
• Negative Sentiment: Investor focus remains on safety concerns around Tavneos after reported patient deaths in Japan prompted restrictions on new prescriptions and raised the risk of withdrawal requests in the U.S., creating a potential earnings and sentiment headwind for Amgen. A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
• Negative Sentiment: News that doctors in Japan could again prescribe Tavneos to new patients only partially eases concerns, because the drug still carries liver-injury warnings and the broader safety controversy may continue to pressure sentiment. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.